Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03737812 (ClinicalTrials.gov)	February 27, 2019	6/11/2018	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie	NULL	Completed	18 Years	65 Years	All	123	Phase 2	United States;Canada
2	NCT03737851 (ClinicalTrials.gov)	December 11, 2018	6/11/2018	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie	NULL	Completed	18 Years	65 Years	All	208	Phase 2	United States;Canada
3	NCT03073603 (ClinicalTrials.gov)	April 20, 2017	18/1/2017	Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)	Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Discontinuation of disease modifying therapy;Drug: Standard of Care	University of Colorado, Denver	Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society;University of Alabama at Birmingham	Completed	55 Years	N/A	All	259	Phase 4	United States
4	NCT01759602 (ClinicalTrials.gov)	January 2013	29/12/2012	C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation	Phase 1b Study of C1-esterase Inhibitor (Cinryze) With Standard of Care for Acute Treatment of Neuromyelitis Optica Exacerbations	Neuromyelitis Optica	Drug: C1-esterase inhibitor (Cinryze)	Michael Levy	ViroPharma	Completed	18 Years	65 Years	All	10	Phase 1	United States
5	NCT00559702 (ClinicalTrials.gov)	October 2007	7/11/2007	Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)	A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: natalizumab;Other: standard of care	Biogen Idec	Elan Pharmaceuticals	Completed	18 Years	65 Years	Both	76	Phase 1	United States